SECURITIES AND EXCHANGE COMMISSION

                        WASHINGTON, D.C.  20549


                            ---------------


                               FORM 8-K

                            CURRENT REPORT




                Pursuant to Section 13 or 15(d) of the
                   Securities Exchange Act of 1934



Date of Report (Date of earliest event reported) October 15, 1997
                                                 ----------------

                   BIOJECT MEDICAL TECHNOLOGIES INC.
         --------------------------------------------------
          (Exact Name of Registrant as Specified in Charter)


                            Oregon
          ----------------------------------------------
          (State or Other Jurisdiction of Incorporation)



       0-15360                            93-1099680
- ------------------------         --------------------------------
(Commission File Number)        (IRS Employer Identification No.)



7620 SW Bridgeport Road
Portland, Oregon                                 97224
- ------------------------------             -----------------
(Address of Principal Executive Offices)      (Zip Code)



Registrant's telephone number, including area code (503) 639-7221
                                                    -------------


                                 N/A
    -------------------------------------------------------------
    (Former Name or Former Address, if Changed Since Last Report)




Item 5.  Other Events

As reported by the Company on Form 8-K filed with the SEC on 
October 3, 1997, the Company executed an agreement on September 
30, 1997 with Elan Corporation, plc, for the license, development and 
commercialization of certain technology related to a continuous glucose 
level monitoring system for diabetics(the "Agreement").  The closing 
of the transactions contemplated by the Agreement occurred on 
October 15, 1997.  

At the time of closing, Bioject issued to Elan International 
Services, Ltd. 2,727,273 shares of Bioject's common stock and a 
five-year warrant to purchase an additional 1,750,000 
shares of common stock at $2.50 per share for an aggregate 
purchase price of $3,000,000.

As previously reported, the project will be conducted in a joint 
venture company that is a new subsidiary of Bioject, owned 19.9 
percent by Elan.  The new company has licensed Elan's glucose 
monitoring technology for an initial payment of $15 million. Elan 
invested approximately $3 million in the subsidiary and Bioject 
invested approximately $12 million. Elan loaned Bioject $12.015 
million, the principal amount and accrued interest of which will 
be exchanged for convertible preferred stock of Bioject if 
Bioject's shareholders approve the exchange.  Bioject is in the process
of preparing a proxy statement in order to call a special meeting of its
shareholders to consider and approve such exchange.

Bioject anticipates taking a charge to expense for the amount of the 
$15 million licensing fee, of which $12.015 million is reportable 
against Bioject's consolidated results of operations.  The difference 
between the aggregate amount of the licensing fee and the reportable 
net amount by Bioject represents the portion of the fee
allocable to the minority interest in the subsidiary.

 
                             Signatures


Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be
signed  on its behalf by the undersigned, thereunto  duly
authorized.


     DATED this 21st day of October, 1997


               BIOJECT MEDICAL TECHNOLOGIES INC.


               By   /s/ Peggy J. Miller
                    Peggy J. Miller
                    Vice  President, Chief
                    Financial Officer and Secretary